-
Abbott/Watson's domestic mRNA vaccine launches phase III clinical trials in China
Time of Update: 2021-08-02
On May 11, 2020, Watson Bio and Abbio reached a cooperation agreement on the joint development of RNA vaccines, and are committed to jointly conducting preclinical research, clinical research and commercial implementation of new coronavirus mRNA vaccines.
-
Boji Pharmaceutical: Wholly-owned subsidiary obtains invention patent certificate
Time of Update: 2021-08-02
On July 20, Boji Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary, New Drug Co.
The invention relates to the application of cardamine and its extract in the preparation of medicines for preventing or treating arrhythmia, and belongs to the field of biomedicine technology .
-
Cinda Bio-PD-1 and Ipilimumab-like drugs are approved for clinical use in nasopharyngeal carcinoma
Time of Update: 2021-08-02
Currently, according to the Insight database, Cinda has carried out 6 clinical trials of IBI310 combined with Sintilimab in China for hepatocellular carcinoma, cervical cancer, postoperative adjuvant melanoma, and dMMR/MSI-H advanced colorectal cancer .
-
National Medical Insurance Administration: Significant achievements have been made in the standardization of medical insurance information business
Time of Update: 2021-08-02
According to reports, through the unification of data coding standards and mutual recognition of data, a unified national medical insurance information platform will be built, which will further optimize and improve the work of cross-provincial medical treatment and online medical insurance business generalization, and form big data at the national and regional levels .
-
TOP10 ammunition equipment for pharmaceutical companies in the first half of 2021
Time of Update: 2021-08-02
In the first half of 2021, Hengrui has 21 products approved for clinical trials, including 15 chemical drugs and 6 biological products .
16 products were approved for clinical trials in China in the first half of the year, of which biological products accounted for 9 and 7 chemical drugs .
-
Hebo Pharmaceutical announced the new CFO and was responsible for the medical business of multiple investment institutions
Time of Update: 2021-08-02
Prior to this, she held senior management positions in the healthcare field in many major global investment banks, such as UBS Investment Bank (New York), Royal Bank of Scotland, ABN AMRO (Hong Kong) and Deutsche Bank (Hong Kong).
-
Medicilon appoints Dr. Xuedong Dai as Executive Vice President of International R&D Services
Time of Update: 2021-08-02
Dai Xuedong as Executive Vice President of Medicilon International R&D Services .
Dai Xuedong involved in the drug research and development has been chaired marketed drugs, such as Horizant / Regnite; clinical drugs such as JNJ-75276617; clinical candidate compounds, such as Arbaclofen Placarbil, XP21279, XP23829 and so on .
-
Bayer Verizikari is approved in the EU for the treatment of symptomatic chronic heart failure
Time of Update: 2021-08-02
Verizilq is a soluble guanylate cyclase stimulant for the treatment of adult patients with symptomatic chronic heart failure (after a decrease in ejection fraction, a recent decompensation event requiring intravenous therapy has stabilized) .
Therefore, new therapies developed for these patients have been approved.
-
Haisco Compound Amino Acid Injection (18AA-Ⅶ) passed the consistency evaluation of generic drugs
Time of Update: 2021-08-02
, has recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, compound amino acid injection (18AA- Ⅶ) Pass the consistency evaluation of generic drugs .
-
Pinguhong injection, a wholly-owned subsidiary of Buchang Pharmaceutical, withdrew from the provincial medical insurance catalogue
Time of Update: 2021-08-02
On July 21, Buchang Pharmaceutical issued an announcement stating that the wholly-owned subsidiary Tonghua Guhong Pharmaceutical Guhong Injection will be transferred out of Hebei Province Medical Insurance Catalog on June 30, 2021 .
-
Development of a new indication for dimethyl fumarate: Sword finger diffuse large B-cell lymphoma
Time of Update: 2021-08-02
Recently, with the deepening of research, drug developers have discovered that dimethyl fumarate has the potential to treat multiple diseases in addition to multiple sclerosis, such as reducing myocardial damage, protecting diabetic cardiomyopathy, and the recently discovered diffuse large B Therapeutic effect of cell lymphoma .
-
One billion retail oral hypoglycemic drugs fall into the "sacred altar" Zhengda Tianqing, Beite... hit the first imitation
Time of Update: 2021-08-02
Text | Bai YuAccording to data from Mi Nei, in 2020, the sales scale of the terminal oral diabetic chemical drugs in Chinese urban physical pharmacies exceeds 6 billion yuan, and 12 of the TOP20 products have sales of more than 100 million yuan.
-
Irinotecan Hydrochloride Injection, a subsidiary of Jingfeng Pharmaceutical, passed the consistency evaluation of generic drugs
Time of Update: 2021-08-02
Irinotecan hydrochloride injection is suitable for the treatment of patients with advanced colorectal cancer.
It can be combined with 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal cancer who have not received chemotherapy before; it can also be used as a single drug to treat patients with 5-fluorouracil-containing chemotherapy regimens.
-
The cumulative output value of two vaccine companies in Beijing exceeded 120 billion yuan, driving the industry to maintain rapid growth in the first half of the year
Time of Update: 2021-08-02
In addition to the vaccine industry, in the first half of the year, the added value of Beijing's electronics industry increased by 25.
In addition to the vaccine industry, in the first half of the year, the added value of Beijing's electronics industry increased by 25.
-
Simultaneously targeting TIGIT, PD-1 and PVRIG immune checkpoint combination therapy to complete the first case of administration
Time of Update: 2021-08-02
Note: The original text has been deletedReference materials:[1] Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207.
Retrieved July 19, 2021, from https:// /il/news-releases/compugen-doses-first-patient-in-phase-12-triple-combination-cohort-expansion-of-com701-with-opdivo-and-bristol-myers-squibbs-anti-tigit-antibody -bms-986207-301336286.
-
Hengrui Medicine SHR-1906 injection was approved for clinical use
Time of Update: 2021-08-02
has recently received the approval of the National Medical Products Administration to issue the "Drug Clinical Trial Approval Notice" for SHR-1906 injection, and clinical trials will be launched in the near future .
-
Relieve the patient's cardiac symptoms within two weeks Jixing Pharmaceutical owns R&D rights in Greater China
Time of Update: 2021-08-02
On July 19, 2021, Cytokinetics announced that in patients with obstructive hypertrophic cardiomyopathy (oHCM), its new drug CK-274 has achieved positive top lines in both dose cohorts of phase 2 clinical trials.
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Propranolol Tablets
Time of Update: 2021-08-02
The marketing authorization holders of the above-mentioned drugs shall revise the instructions in accordance with the requirements of the corresponding annexes (see annexes 1 and 2) in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and report to the provincial drug regulatory authority before October 14, 2021 Record .
-
Li Liqun, Chairman of Sino-Singapore Pharmaceuticals, resigns
Time of Update: 2021-08-02
On July 20, Zhongxin Pharmaceutical issued an announcement announcing that the company’s board of directors received a written resignation from Mr.
The company will perform the relevant procedures of by-election of directors and election of chairman of the board as soon as possible in accordance with relevant regulations .
-
Tianjin Boai Biopharmaceuticals fined 3.01 million yuan for producing counterfeit drugs, legal representative was banned for life
Time of Update: 2021-08-02
5 yuan of illegal income; order the suspension of production and business for rectification; and Impose a fine of 30 times the value of illegally produced drugs (91591.
